{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:10Z","timestamp":1792900090877,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"DOI":"10.7759\/cureus.73552","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:57:51Z","timestamp":1731448671000},"source":"Crossref","is-referenced-by-count":1,"title":["Short-Term and Intermediate Efficacy of Tacrolimus for Active Ulcerative Colitis: A Single-Center Retrospective Analysis in Japan"],"prefix":"10.7759","author":[{"given":"Satoshi","family":"Masuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimari","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kojimahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Haruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Irisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi T","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, et al.. Ulcerative colitis. Nat Rev Dis Primers. 2020, 6:74. 10.1038\/s41572-020-0205-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion WA Jr","year":"2001","unstructured":"Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001, 121:255-260. 10.1053\/gast.2001.26279","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"Matsuoka K","year":"2018","unstructured":"Matsuoka K, Kobayashi T, Ueno F, et al.. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018, 53:305-353. 10.1007\/s00535-018-1439-1","journal-title":"J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa172","article-title":"Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016","volume":"15","author":"Matsuoka K","year":"2021","unstructured":"Matsuoka K, Igarashi A, Sato N, et al.. Trends in corticosteroid prescriptions for ulcerative colitis and factors associated with long-term corticosteroid use: analysis using Japanese claims data from 2006 to 2016. J Crohns Colitis. 2021, 15:358-366. 10.1093\/ecco-jcc\/jjaa172","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase H","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, et al.. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021, 56:489-526. 10.1007\/s00535-021-01784-1","journal-title":"J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino T","year":"1987","unstructured":"Kino T, Hatanaka H, Hashimoto M, et al.. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987, 40:1249-1255. 10.7164\/antibiotics.40.1249","journal-title":"J Antibiot (Tokyo)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro","volume":"40","author":"Kino T","year":"1987","unstructured":"Kino T, Hatanaka H, Miyata S, et al.. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987, 40:1256-1265. 10.7164\/antibiotics.40.1256","journal-title":"J Antibiot (Tokyo)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata H","year":"2006","unstructured":"Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006, 55:1255-1262. 10.1136\/gut.2005.081794","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger S","year":"1994","unstructured":"Lichtiger S, Present DH, Kornbluth A, et al.. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994, 330:1841-1855. 10.1056\/NEJM199406303302601","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder KW","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987, 317:1625-1629. 10.1056\/NEJM198712243172603","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310187","article-title":"Development and validation of the Nancy histological index for UC","volume":"66","author":"Marchal-Bressenot A","year":"2017","unstructured":"Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al.. Development and validation of the Nancy histological index for UC. Gut. 2017, 66:43-49. 10.1136\/gutjnl-2015-310187","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03764.x","article-title":"Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis","volume":"28","author":"Yamamoto S","year":"2008","unstructured":"Yamamoto S, Nakase H, Mikami S, et al.. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008, 28:589-597. 10.1111\/j.1365-2036.2008.03764.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12118","article-title":"Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients","volume":"37","author":"Schmidt KJ","year":"2013","unstructured":"Schmidt KJ, Herrlinger KR, Emmrich J, et al.. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013, 37:129-136. 10.1111\/apt.12118","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16006","article-title":"Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus","volume":"38","author":"Takatsu N","year":"2023","unstructured":"Takatsu N, Hisabe T, Kishi M, et al.. Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus. J Gastroenterol Hepatol. 2023, 38:52-60. 10.1111\/jgh.16006","journal-title":"J Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord M","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al.. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017, 11:769-784. 10.1093\/ecco-jcc\/jjx009","journal-title":"J Crohns Colitis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.08.081","article-title":"Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis","volume":"17","author":"Pellet G","year":"2019","unstructured":"Pellet G, Stefanescu C, Carbonnel F, et al.. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2019, 17:494-501. 10.1016\/j.cgh.2018.08.081","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000195","article-title":"Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis","volume":"5","author":"Hamel B","year":"2018","unstructured":"Hamel B, Wu M, Hamel EO, Bass DM, Park KT. Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis. BMJ Open Gastroenterol. 2018, 5:e000195. 10.1136\/bmjgast-2017-000195","journal-title":"BMJ Open Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone S","year":"2011","unstructured":"Ardizzone S, Cassinotti A, Duca P, et al.. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011, 9:483.e3-489.e3. 10.1016\/j.cgh.2010.12.028","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel JF","year":"2011","unstructured":"Colombel JF, Rutgeerts P, Reinisch W, et al.. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011, 141:1194-1201. 10.1053\/j.gastro.2011.06.054","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2016.1141315","article-title":"Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis","volume":"51","author":"Takahashi F","year":"2016","unstructured":"Takahashi F, Tominaga K, Kanamori A, et al.. Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis. Scand J Gastroenterol. 2016, 51:827-834. 10.3109\/00365521.2016.1141315","journal-title":"Scand J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy300","article-title":"Efficacy of therapeutic intervention for patients with an ulcerative colitis mayo endoscopic score of 1","volume":"25","author":"Fukuda T","year":"2019","unstructured":"Fukuda T, Naganuma M, Sugimoto S, et al.. Efficacy of therapeutic intervention for patients with an ulcerative colitis mayo endoscopic score of 1. Inflamm Bowel Dis. 2019, 25:782-788. 10.1093\/ibd\/izy300","journal-title":"Inflamm Bowel Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.66","article-title":"Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test","volume":"110","author":"Takashima S","year":"2015","unstructured":"Takashima S, Kato J, Hiraoka S, et al.. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015, 110:873-880. 10.1038\/ajg.2015.66","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313538-short-term-and-intermediate-efficacy-of-tacrolimus-for-active-ulcerative-colitis-a-single-center-retrospective-analysis-in-japan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:57:52Z","timestamp":1731448672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313538-short-term-and-intermediate-efficacy-of-tacrolimus-for-active-ulcerative-colitis-a-single-center-retrospective-analysis-in-japan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.73552","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}